Unknown

Dataset Information

0

Preemptive interleukin-6 blockade in patients with COVID-19.


ABSTRACT: Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score?

SUBMITTER: Guillen L 

PROVIDER: S-EPMC7545205 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated earl  ...[more]

Similar Datasets

| S-EPMC7428300 | biostudies-literature
| S-EPMC7320867 | biostudies-literature
| S-EPMC8078877 | biostudies-literature
| S-EPMC7608031 | biostudies-literature
| S-BSST416 | biostudies-other
| S-EPMC9265168 | biostudies-literature
| S-BSST1269 | biostudies-other
| S-EPMC9511465 | biostudies-literature
| S-EPMC9592141 | biostudies-literature
| S-BSST719 | biostudies-other